Clinical Trials Logo

Proteinuria clinical trials

View clinical trials related to Proteinuria.

Filter by:

NCT ID: NCT04874753 Completed - Covid19 Clinical Trials

The Effect of COVID-19 Pandemia on Follow up of Patients With Chronic Kidney Disease

COVID19-CKD
Start date: November 3, 2020
Phase:
Study type: Observational

COVID-19 pandemic affected the admission of patients to the hospital especially the older patients (> 65 years old) because of curfews and the reluctance of patients to apply to the hospitals. Chronic kidney disease is characterized with the progressive loss of kidney function over the time and regular follow-up of patients for their kidney function and treatment of complications is recommended in these patients.

NCT ID: NCT04752293 Recruiting - Hypertension Clinical Trials

Pediatric Hypertension and the Renin-Angiotensin SystEm (PHRASE)

PHRASE
Start date: May 19, 2021
Phase:
Study type: Observational

Studying the causal roles of components of the renin-angiotensin-aldosterone system (including angiotensin-(1-7) (Ang-(1-7)), angiotensin-converting enzyme 2 (ACE2), Ang II, and ACE), uric acid, and klotho in pediatric hypertension and related target organ injury, including in the heart, kidneys, vasculature, and brain. Recruiting children with a new hypertension diagnosis over a 2-year period from the Hypertension and Pediatric Nephrology Clinics affiliated with Brenner Children's Hospital at Atrium Health Wake Forest Baptist and Atrium Health Levine Children's Hospital. Healthy control participants will be recruited from local general primary care practices. Collecting blood and urine samples to analyze components of the renin-angiotensin-aldosterone system (Ang-(1-7), ACE2, Ang II, ACE), uric acid, and klotho, and measuring blood pressure, heart structure and function, autonomic function, vascular function, and kidney function at baseline, year 1, and year 2. Objectives are to investigate phenotypic and treatment response variability and to causally infer if Ang-(1-7), ACE2, Ang II, ACE, uric acid, and klotho contribute to target organ injury due to hypertension.

NCT ID: NCT04534270 Completed - Proteinuria Clinical Trials

Efficacy and Safety of Dapagliflozin in Children With Proteinuria

Start date: July 6, 2020
Phase: Phase 4
Study type: Interventional

The purpose of the study is to investigate the antiproteinuric effect of Dapagliflozin in children with proteinuria.

NCT ID: NCT04531397 Withdrawn - Clinical trials for Chronic Kidney Diseases

Efficacy and Safety of Dapagliflozin in Children With Proteinuric Chronic Kidney Disease

Start date: January 1, 2021
Phase: Phase 4
Study type: Interventional

We aim to investigate the antiproteinuric effect of adding Dapagliflozin to the standard of care in children with proteinuria.

NCT ID: NCT04456816 Recruiting - Clinical trials for Severe Proteinuria Due to Idiopathic Membranous Nephropathy

A Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Treatment With AP1189 in Patients With iMN and Severe Proteinuria

Start date: August 31, 2020
Phase: Phase 2
Study type: Interventional

This study is an exploratory, randomized, double-blind, multicenter, placebo-controlled study with repeated doses of AP1189. The study population will consist of patients with idiopathic membranous nephropathy (iMN) and severe proteinuria who are on ACE inhibitor or angiotensin II receptor blocker treatment.

NCT ID: NCT04171778 Terminated - Proteinuria Clinical Trials

Effects of Whole Food, Plant-Based Nutrition on Chronic Kidney Disease With Proteinuria

Start date: December 5, 2019
Phase: N/A
Study type: Interventional

This study will test the hypothesis that lifestyle intervention consisting of a whole food, plant-based (WFPB) diet and group education will favorably impact outcomes germane to individuals with chronic kidney disease (CKD) stage 3b and 4, including blood pressure control, amount of proteinuria (protein in the urine), and preservation of glomerular filtration rate (GFR). In addition, this study will assess weight and body composition, diabetic control in subjects with diabetes as well as CKD, and quality of life. Safety of a WFPB diet in subjects with CKD will be tested with respect to the development of elevated serum potassium and phosphorus, hypoalbuminemia (low blood protein), hypotension (low blood pressure), and hypoglycemia (low blood sugar). An exploratory aim is to test the effects of a WFPB diet on the microbiome of subjects by collecting and analyzing stool samples.

NCT ID: NCT04169776 Completed - Clinical trials for Idiopathic Nephrotic Syndrome

Effect of Daily Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) on Proteinuria in Pediatric Patients With Idiopathic Nephrotic Syndrome

taVNS
Start date: December 1, 2019
Phase: N/A
Study type: Interventional

This study evaluates the impact of transcutaneous auricular Vagus Nerve stimulation (taVNS) therapy on the incidence of nephrotic syndrome relapses in children with idiopathic nephrotic syndrome. Participants will perform taVNS 5 minutes a day for 6 months total, monitoring for signs of nephrotic syndrome relapse with both labwork and clinical symptoms.

NCT ID: NCT04059211 Completed - Proteinuria Clinical Trials

Sensitivity and Specificity of Urinary Dipstick in Emergency Departments

Start date: April 1, 2019
Phase:
Study type: Observational

Urinary dipsticks are commonly used in emergency departments since they are a cheap and quick diagnostic tool. However the sensitivity and specificity of urinary dipsticks might be compromised in emergency departments due to fluid imbalance and acute illness itself.

NCT ID: NCT04058951 Recruiting - Hypertension Clinical Trials

Plant Versus Animal Dietary Protein and the Effect on Proteinuria

NYPRO
Start date: August 15, 2019
Phase: N/A
Study type: Interventional

The purpose of this study is to investigate if a diet high in plant protein improves kidney function in patients with kidney insufficiency and diabetes and/or hypertension and/or glomerulonephritis. The study is a non-blinded, randomized, controlled, cross-over-design with two intervention periods of each 14 days. Between the two interventions periods there is a washout period of 14 days. The participants are randomized to start with an individualized diet plan containing either high amounts of animal protein or high amounts of plant protein.

NCT ID: NCT04051957 Terminated - Hypertension Clinical Trials

Isosorbide Mononitrate For Anti-Vascular Endothelial Growth Factor (VEGF) Induced Kidney Injury

Start date: September 26, 2019
Phase: Phase 2
Study type: Interventional

The purpose of this study is to test the hypothesis that isosorbide mononitrate prevents deterioration of renal function in patients receiving anti-angiogenic therapies that target vascular endothelial growth factor (VEGF).